Therapeutic vaccines against HIV need international partnerships (original) (raw)

• Autran, B., Carcelain, G., Li., T. S., Blanc, C. & Mathez, D. Positive effects of combined anti-retroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112–116 (1997).
  Article CAS Google Scholar
• Palella, F. J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853–860 (1998).
  Article Google Scholar
• Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512–517 (1999).
  Article CAS Google Scholar
• Shafer, R. W. et al. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128, 906–911 (1998).
  Article CAS Google Scholar
• Carr, A. et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS 12, 51F–58F (1998).
  Article Google Scholar
• Brinkman, K. et al. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354, 1112–1114 (1999).
  Article CAS Google Scholar
• Yeni, P. G. et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288, 222–235 (2002).
  Article CAS Google Scholar
• Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655 (1994).
  CAS PubMed PubMed Central Google Scholar
• Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860 (1999).
  Article CAS Google Scholar
• Rosenberg, E. S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447–1450 (1997).
  Article CAS Google Scholar
• Lyles, R. H. et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS cohort study. J. Infect. Dis. 181, 872–880 (2000).
  Article CAS Google Scholar
• Parren, P. W., Moore, J. P., Burton, D. R. & Sattentau, Q. J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 S137–S162 (1999).
  CAS PubMed Google Scholar
• Rinaldo, C. R. et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term non progressors. J. Virol. 69, 5838–5842 (1995).
  CAS PubMed PubMed Central Google Scholar
• Harrer, T. et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 156, 2616–2623 (1996).
  CAS PubMed Google Scholar
• Jouan, M. et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15, 23–31 (2001).
  Article CAS Google Scholar
• Rosenberg, E. S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523–526 (2000).
  Article CAS Google Scholar
• Altfeld, M. et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193, 169–180 (2001).
  Article CAS Google Scholar
• Oxenius, A. et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 97, 3382–3387 (2000).
  Article CAS Google Scholar
• Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95–98 (2002).
  Article CAS Google Scholar
• Ogg, G. S. et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797–800 (1999).
  CAS PubMed PubMed Central Google Scholar
• Mollet, L. et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. J. Immunol. 165, 1692–1704 (2000).
  Article CAS Google Scholar
• Carcelain, G. et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J. Virol. 75, 234–241 (2001).
  Article CAS Google Scholar
• Ruiz, L. et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15, F19–F27 (2001).
  Article CAS Google Scholar
• Oxenius, A. et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl Acad. Sci. USA 99, 13747–13752 (2002).
  Article CAS Google Scholar
• Markowitz, M. et al. Discontinuation of antiretroviral therapy commenced early in the course of human immunodeficiency virus type I infection, with or without adjunctive vaccination. J. Infect. Dis. 186, 634–643 (2002).
  Article CAS Google Scholar
• Altfeld, M. et al. HIV-1 superinfection despite broad CD8+ T cell responses containing replication of the primary virus. Nature 420, 434–439 (2002).
  Article CAS Google Scholar
• Autran, B. & Carcelain, G. AIDS. Boosting immunity to HIV: can the virus help? Science 290, 946–949 (2000).
  Article CAS Google Scholar
• Hel, Z. et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV231 infection of macaques. Nature Med. 6, 1140–1146 (2000).
  Article CAS Google Scholar
• Tryniszewska, E. et al. Vaccination of macaques with long-standing SIVmac251 infection lowers viral set point after cessation of antiretroviral therapy. J. Immunol. 169, 5347–5357 (2002).
  Article Google Scholar
• MacGregor, R. R. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1-infection: safety and host response. J. Infect. Dis. 100, 178–192 (1998).
  Google Scholar
• Jin, X. et al. Safety and immunogenicity of ALVAC vCP 1452 and recombinant gp 160 in newly human immunodeficiency virus type I infection, with prolonged highly active antiretroviral therapy. J. Virol. 76, 2206–2216 (2002).
  Article CAS Google Scholar
• Tubiana, R. et al. Therapeutic vaccination with ALVAC-HIV vCP1433: a recombinant canarypox vaccine in chronically HIV-1 infected patients treated with HAART: VACCITER (ANRS 094) Abstr. 61, 10th Conference in retroviruses and opportunistic infections, Boston (2003).
• Levy, Y. et al. Immunological and virological efficacy of ALVAC-VIH 1433 and HIV lipopeptides (lipo-6T) combined with SC IL-2 in chronically HIV-infected patients – results of the ANRS 093 randomized study. Abstr. 62, 10th Conference in retroviruses and opportunistic infections, Boston (2003).
• Le Garff, M. et al. Cross recognition of HIV-specific CD8 responses in chronically HIV-1 infected patients immunized by an HIV-1–LAI recombinant canarypox vector (vCP1433) Abstr. 646, 10th Conference in retroviruses and opportunistic infections, Boston (2003).
• Robbins, G., Walker, B. & Rosenberg, E. Augmentation of HIV-1-specific TH cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS (in the press)
• Goh, L. E. et al. The QUEST trial, a paradigm of HIV collaborative research. Nature Med. 11, 1194 (2000).
  Article Google Scholar
• Lu, W. et al. Therapeutic dendritic-cell vaccine for simian AIDS. Nature Med. 9, 27–32 (2003).
  Article CAS Google Scholar
• Bhardwaj, N. & Walker, B. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine. Nature Med. 9, 13–14 (2003).
  Article CAS Google Scholar
• Dove, A. IAVI advances AIDS vaccine research. International AIDS Vaccine Initiative. Nature Med. 1, 5 (1999).
  Google Scholar